AMGN

Business Context and Reporting Period

Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Amgen is a global biotechnology company discovering, developing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL. The company operates in a single segment: human therapeutics.

Key Financial Metrics

Margins: Operating margin was approximately 39.2% for Q1 2008. Cost of sales decreased to 15% of product sales from 17% in the prior year. R&D expenses decreased to 20% of product sales from 24%.

Material Changes vs. Prior Period

• Revenue Decline: Total product sales decreased 1% to $3.537 billion. This was driven by a 38% decline in U.S. Aranesp sales ($249 million decrease) due to regulatory and reimbursement restrictions on erythropoiesis-stimulating agents (ESAs). This decline was partially offset by a 30% increase in ENBREL sales ($221 million increase), aided by a shift to a wholesaler distribution model.
• Expense Reductions: R&D expenses dropped 18% to $694 million, attributed to restructuring cost savings, cost recoveries from licensing transactions, and the completion of enrollment in large clinical trials. SG&A expenses increased 14% to $874 million, primarily due to higher profit-sharing expenses with co-promoter Wyeth resulting from increased ENBREL sales.
• Restructuring: The company incurred $12 million in restructuring charges in Q1 2008. Cumulative charges through March 31, 2008, totaled $751 million against an estimated total of $775 million to $825 million.
• Acquisition: Completed the acquisition of the remaining 51% of Dompé Biotec, S.p.A. on January 4, 2008, for approximately $162 million.

Guidance, Outlook, and Risks

Management Commentary: Management expects the restructuring plan to be substantially completed in 2008. The company is refocusing spending on critical R&D and operational priorities. Capital expenditures for 2008 are estimated at approximately $900 million.

Key Risks and Contingencies:

• ESA Regulatory Environment: Significant ongoing challenges regarding Aranesp and EPOGEN. The FDA has requested additional safety-related label changes, a Risk Evaluation and Mitigation Strategy (REMS), and clinical trials to determine effects on survival and tumor outcomes. The CMS Claims Monitoring Policy (EMP) implemented in January 2008 reduced reimbursement for patients with high hemoglobin levels and lowered dosing limits.
• Legal Proceedings:
  • Roche Matters: A preliminary injunction preventing Roche from commercializing MIRCERA in the U.S. was upheld, but Roche has appealed. Amgen is seeking a permanent injunction.
  • AWP Litigation: A tentative class settlement was reached in the Average Wholesale Price (AWP) Multi-District Litigation.
• Accounting Changes: Potential adoption of new FASB standards regarding cash-settled convertible debt could materially reduce reported net income in the future by requiring bifurcation of debt and equity components.
• Competition: Anticipated launch of biosimilar G-CSF products in the EU in 2008, which may compete with Neulasta and NEUPOGEN.

Investor Verification Checklist

• ESA Sales Trajectory: Verify the extent of the decline in U.S. Aranesp sales and the impact of the new CMS EMP policy on future revenue.
• Regulatory Outcomes: Monitor the FDA's final decisions on the requested REMS and label changes for Aranesp and EPOGEN following the March 2008 ODAC meeting.
• Restructuring Completion: Confirm the final total cost of the restructuring plan and the realization of anticipated cost savings in subsequent quarters.
• Convertible Debt Accounting: Assess the potential impact of the proposed FASB Staff Position on convertible debt accounting on future earnings per share.
• ENBREL Sustainability: Evaluate whether the 30% sales increase in ENBREL is sustainable after the one-time impact of wholesaler inventory stocking.